[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1473
86. Ishiguro K, Shyam K, Penketh PG, Sartorelli AC: Development of an O(6)-alkylguanine-DNA alkyltransferase assay based on covalent transfer of the benzyl moiety from [benzene-3H]O(6)-benzylguanine to the protein. Anal Biochem; 2008 Dec 1;383(1):44-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although it is known that (i) O(6)-alkylguanine-DNA alkyltransferase (AGT) confers tumor cell resistance to guanine O(6)-targeting drugs such as cloretazine, carmustine, and temozolomide and that (ii) AGT levels in tumors are highly variable, measurement of AGT activity in tumors before treatment is not a routine clinical practice.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochemistry. 1996 Jan 30;35(4):1328-34 [8573590.001]
  • [Cites] Cancer Res. 1995 Sep 15;55(18):4085-91 [7664284.001]
  • [Cites] Carcinogenesis. 1996 Feb;17(2):219-24 [8625442.001]
  • [Cites] J Med Chem. 1996 Dec 20;39(26):5192-201 [8978847.001]
  • [Cites] Cancer Treat Rev. 1997 Jan;23(1):35-61 [9189180.001]
  • [Cites] Cancer Res. 1997 Sep 1;57(17):3672-7 [9288770.001]
  • [Cites] Cancer Invest. 1997;15(6):588-98 [9412665.001]
  • [Cites] J Med Chem. 1998 Dec 17;41(26):5265-71 [9857094.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Mol Cancer Ther. 2005 Nov;4(11):1755-63 [16275997.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):25-31 [17146105.001]
  • [Cites] J Invest Dermatol. 2007 Apr;127(4):751-61 [17218941.001]
  • [Cites] DNA Repair (Amst). 2007 Aug 1;6(8):1071-8 [17482892.001]
  • [Cites] Br Med Bull. 2008;85:17-33 [18245773.001]
  • [Cites] Biochem Pharmacol. 2000 Feb 1;59(3):283-91 [10609557.001]
  • [Cites] Mutat Res. 2000 Apr;462(2-3):83-100 [10767620.001]
  • [Cites] Methods Mol Biol. 2000;152:49-61 [10957968.001]
  • [Cites] J Pharmacol Exp Ther. 2001 May;297(2):524-30 [11303039.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3033-8 [11306484.001]
  • [Cites] Chembiochem. 2001 Apr 2;2(4):285-7 [11828457.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2388-99 [11981013.001]
  • [Cites] Carcinogenesis. 2002 May;23(5):823-30 [12016156.001]
  • [Cites] Carcinogenesis. 2003 Apr;24(4):625-35 [12727789.001]
  • [Cites] Anal Biochem. 2003 Oct 1;321(1):38-43 [12963053.001]
  • [Cites] Cell. 1976 Jun;8(2):263-9 [971485.001]
  • [Cites] J Biol Chem. 1983 Feb 25;258(4):2327-33 [6822564.001]
  • [Cites] Cancer Lett. 1984 Jun;23(2):213-21 [6744245.001]
  • [Cites] J Cell Physiol. 1984 Nov;121(2):383-90 [6593322.001]
  • [Cites] Carcinogenesis. 1986 May;7(5):745-9 [3698202.001]
  • [Cites] Cancer Res. 1987 Dec 1;47(23):6229-35 [2824027.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368-72 [2164681.001]
  • [Cites] Mutat Res. 1990 Nov-Dec;233(1-2):117-26 [2233793.001]
  • [Cites] Cancer Res. 1991 Aug 15;51(16):4131-4 [1868433.001]
  • [Cites] J Mol Biol. 1993 Jun 20;231(4):950-9 [8515475.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3416-20 [8324751.001]
  • [Cites] Biochemistry. 1993 Nov 16;32(45):11998-2006 [8218276.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6221-7 [7954470.001]
  • [Cites] J Med Chem. 1996 Feb 2;39(3):796-801 [8576923.001]
  • (PMID = 18783719.001).
  • [ISSN] 1096-0309
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090671-02; United States / NCI NIH HHS / CA / R01 CA122112; United States / NCI NIH HHS / CA / CA090671-03; United States / NCI NIH HHS / CA / CA129186-020001; United States / NCI NIH HHS / CA / R01 CA090671-07; United States / NCI NIH HHS / CA / CA-090671; United States / NCI NIH HHS / CA / CA-129186; United States / NCI NIH HHS / CA / R01 CA122112-02; United States / NCI NIH HHS / CA / R01 CA090671-06; United States / NCI NIH HHS / CA / CA090671-04; United States / NCI NIH HHS / CA / CA122112-03; United States / NCI NIH HHS / CA / R01 CA090671-01A1; United States / NCI NIH HHS / CA / P01 CA129186-010001; United States / NCI NIH HHS / CA / CA090671-06; United States / NCI NIH HHS / CA / R01 CA090671-02; United States / NCI NIH HHS / CA / CA122112-02; United States / NCI NIH HHS / CA / R01 CA122112-03; United States / NCI NIH HHS / CA / R01 CA090671-03; United States / NCI NIH HHS / CA / CA129186-010001; United States / NCI NIH HHS / CA / R01 CA122112-01; United States / NCI NIH HHS / CA / P01 CA129186; United States / NCI NIH HHS / CA / CA090671-01A1; United States / NCI NIH HHS / CA / R01 CA090671; United States / NCI NIH HHS / CA / CA090671-05; United States / NCI NIH HHS / CA / CA122112-01; United States / NCI NIH HHS / CA / R01 CA090671-04; United States / NCI NIH HHS / CA / P01 CA129186-020001; United States / NCI NIH HHS / CA / CA090671-07; United States / NCI NIH HHS / CA / CA-122112; United States / NCI NIH HHS / CA / R01 CA090671-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteins; 19916-73-5 / O(6)-benzylguanine; 5Z93L87A1R / Guanine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  • [Other-IDs] NLM/ NIHMS84728; NLM/ PMC2773450
  •  go-up   go-down


87. Lee MC, Nelson SJ: Supervised pattern recognition for the prediction of contrast-enhancement appearance in brain tumors from multivariate magnetic resonance imaging and spectroscopy. Artif Intell Med; 2008 May;43(1):61-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supervised pattern recognition for the prediction of contrast-enhancement appearance in brain tumors from multivariate magnetic resonance imaging and spectroscopy.
  • OBJECTIVE: The purpose of this study was to develop a pattern classification algorithm for use in predicting the location of new contrast-enhancement in brain tumor patients using data obtained via multivariate magnetic resonance (MR) imaging from a prior scan.
  • METHODS AND MATERIALS: Contrast-enhanced MR images, perfusion images, diffusion images, and proton spectroscopic imaging data were obtained from 26 patients with glioblastoma multiforme brain tumors, divided into a design set and an unseen test set for verification of results.
  • A genetic algorithm was implemented to select optimal features and feature weights for the k-NN algorithm.
  • Each individual parameter was thresholded as a simple classification technique, and the results compared with the k-NN.
  • The k-NN results had lower variation across patients than the single-variable classifiers.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1996 Mar;84(3):449-58 [8609557.001]
  • [Cites] Radiology. 1994 Apr;191(1):41-51 [8134596.001]
  • [Cites] Neuroreport. 1996 Jul 8;7(10):1597-600 [8904763.001]
  • [Cites] Med Phys. 1996 Oct;23(10):1671-84 [8946365.001]
  • [Cites] Magn Reson Med. 1997 Aug;38(2):311-21 [9256113.001]
  • [Cites] Neuroradiology. 1997 Jul;39(7):483-9 [9258924.001]
  • [Cites] NMR Biomed. 1998 Jun-Aug;11(4-5):177-91 [9719572.001]
  • [Cites] NMR Biomed. 1998 Jun-Aug;11(4-5):192-200 [9719573.001]
  • [Cites] Radiology. 1999 Jun;211(3):791-8 [10352608.001]
  • [Cites] NMR Biomed. 2005 Feb;18(1):34-43 [15657908.001]
  • [Cites] J Magn Reson. 2005 Apr;173(2):218-28 [15780914.001]
  • [Cites] Artif Intell Med. 2005 Mar;33(3):223-36 [15811787.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1446-54 [15956514.001]
  • [Cites] Magn Reson Med. 2005 Sep;54(3):616-24 [16088879.001]
  • [Cites] J Magn Reson Imaging. 2006 Mar;23(3):257-66 [16456821.001]
  • [Cites] Med Phys. 2006 Apr;33(4):868-75 [16696462.001]
  • [Cites] IEEE Trans Med Imaging. 1999 Aug;18(8):712-21 [10534053.001]
  • [Cites] Magn Reson Med. 2000 Jan;43(1):23-33 [10642728.001]
  • [Cites] Nat Med. 2000 Nov;6(11):1287-9 [11062544.001]
  • [Cites] J Magn Reson Imaging. 2001 Feb;13(2):167-77 [11169821.001]
  • [Cites] Magn Reson Med. 2001 Aug;46(2):228-39 [11477625.001]
  • [Cites] J Neurosurg. 2002 Oct;97(4):794-802 [12405365.001]
  • [Cites] J Neurol Sci. 2003 Dec 15;216(1):1-10 [14607296.001]
  • [Cites] Anal Chem. 2003 Oct 15;75(20):5352-61 [14710812.001]
  • [Cites] Radiology. 1982 Apr;143(1):29-36 [7063747.001]
  • [Cites] Radiology. 1993 Mar;186(3):745-52 [8430183.001]
  • [Cites] Radiology. 1993 Oct;189(1):233-8 [8372199.001]
  • [Cites] AJR Am J Roentgenol. 1994 Mar;162(3):671-7 [8109520.001]
  • [Cites] J Magn Reson B. 1996 Jun;111(3):209-19 [8661285.001]
  • (PMID = 18448318.001).
  • [ISSN] 0933-3657
  • [Journal-full-title] Artificial intelligence in medicine
  • [ISO-abbreviation] Artif Intell Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA097257-010002; United States / NCI NIH HHS / CA / CA097257-050002; United States / NCI NIH HHS / CA / F32 CA105944-02; United States / NCI NIH HHS / CA / CA097257-020002; United States / NCI NIH HHS / CA / CA097257-060002; United States / NCI NIH HHS / CA / P50 CA097257-050002; United States / NCI NIH HHS / CA / P50 CA097257-060002; United States / NCI NIH HHS / CA / CA105944-01A1; United States / NCI NIH HHS / CA / CA097257-040002; United States / NCI NIH HHS / CA / P50 CA97257; United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / F32 CA105944-01A1; United States / NCI NIH HHS / CA / P50 CA097257-020002; United States / NCI NIH HHS / CA / R01 CA127612; United States / NCI NIH HHS / CA / CA105944-02; United States / NCI NIH HHS / CA / P50 CA097257-030002; United States / NCI NIH HHS / CA / P50 CA097257-040002; United States / NCI NIH HHS / CA / F32 CA105944; United States / NCI NIH HHS / CA / CA097257-030002; United States / NCI NIH HHS / CA / P50 CA097257-010002
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Contrast Media
  • [Other-IDs] NLM/ NIHMS52304; NLM/ PMC3755619
  •  go-up   go-down


88. Guo YB, Li J, Li L, Chen F, Wu W, Wang J, Wang H: Mutations that disrupt either the pqq or the gdh gene of Rahnella aquatilis abolish the production of an antibacterial substance and result in reduced biological control of grapevine crown gall. Appl Environ Microbiol; 2009 Nov;75(21):6792-803
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Anti-Bacterial Agents / biosynthesis. Antibiosis. Glucose Dehydrogenases / biosynthesis. PQQ Cofactor / biosynthesis. Plant Tumors / microbiology. Rahnella / physiology. Vitis / microbiology

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gen Virol. 1975 Jan;26(1):33-48 [1123610.001]
  • [Cites] Proc Natl Acad Sci U S A. 1974 Sep;71(9):3672-6 [4530328.001]
  • [Cites] J Bacteriol. 1986 Jul;167(1):66-72 [3013840.001]
  • [Cites] Appl Environ Microbiol. 1986 Nov;52(5):1183-9 [3098168.001]
  • [Cites] J Bacteriol. 1989 Jan;171(1):447-55 [2536663.001]
  • [Cites] Gene. 1988 Oct 15;70(1):191-7 [2853689.001]
  • [Cites] Annu Rev Nutr. 1990;10:297-318 [2166547.001]
  • [Cites] J Bacteriol. 1990 Nov;172(11):6557-67 [2172216.001]
  • [Cites] Methods Enzymol. 1990;188:260-83 [2177820.001]
  • [Cites] Proc Soc Exp Biol Med. 1991 May;197(1):19-26 [1850521.001]
  • [Cites] Methods Enzymol. 1991;204:384-97 [1658565.001]
  • [Cites] Mol Gen Genet. 1992 Mar;232(2):284-94 [1313537.001]
  • [Cites] J Bacteriol. 1992 Sep;174(18):5814-9 [1325965.001]
  • [Cites] J Biol Chem. 1993 Jun 15;268(17):12812-7 [8509415.001]
  • [Cites] Methods Enzymol. 1994;235:386-405 [8057911.001]
  • [Cites] Biochem J. 1995 Apr 15;307 ( Pt 2):331-3 [7733865.001]
  • [Cites] Appl Environ Microbiol. 1995 Nov;61(11):3856-64 [8526497.001]
  • [Cites] J Bacteriol. 1996 Feb;178(4):1224-6 [8576064.001]
  • [Cites] Mol Plant Microbe Interact. 1996 Jul;9(5):401-8 [8672817.001]
  • [Cites] Int J Food Microbiol. 1996 Jul;30(3):243-53 [8854178.001]
  • [Cites] Microbiology. 1997 Feb;143 ( Pt 2):595-602 [9043136.001]
  • [Cites] FEMS Microbiol Lett. 1998 Feb 1;159(1):121-7 [9485602.001]
  • [Cites] Anal Biochem. 1999 May 1;269(2):317-25 [10222004.001]
  • [Cites] FEMS Microbiol Lett. 1999 Oct 1;179(1):37-42 [10481083.001]
  • [Cites] Biosens Bioelectron. 2005 Jan 15;20(7):1277-84 [15590279.001]
  • [Cites] J Bacteriol. 2006 Nov;188(21):7668-76 [16936032.001]
  • [Cites] Int J Food Microbiol. 2007 Feb 15;113(3):251-7 [17007950.001]
  • [Cites] Plant Physiol. 2008 Feb;146(2):657-68 [18055583.001]
  • [Cites] FEMS Microbiol Lett. 2008 May;282(1):140-6 [18355275.001]
  • [Cites] Phytopathology. 2008 Nov;98(11):1218-25 [18943411.001]
  • [Cites] J Biotechnol. 2001 Nov 30;84(2):155-61 [11090687.001]
  • [Cites] J Nutr. 2000 Apr;130(4):719-27 [10736320.001]
  • [Cites] Appl Environ Microbiol. 2009 Jun;75(12):4162-74 [19376896.001]
  • [Cites] Appl Microbiol Biotechnol. 2002 Jan;58(1):13-22 [11831471.001]
  • [Cites] Appl Environ Microbiol. 2002 Jun;68(6):2637-43 [12039714.001]
  • [Cites] Biochem Pharmacol. 2003 Jan 1;65(1):67-74 [12473380.001]
  • [Cites] Curr Microbiol. 2003 Dec;47(6):457-61 [14756528.001]
  • [Cites] Arch Biochem Biophys. 2004 Aug 1;428(1):2-9 [15234264.001]
  • [Cites] J Mol Biol. 1983 Jun 5;166(4):557-80 [6345791.001]
  • (PMID = 19734331.001).
  • [ISSN] 1098-5336
  • [Journal-full-title] Applied and environmental microbiology
  • [ISO-abbreviation] Appl. Environ. Microbiol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ EF090904/ FJ868974
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / DNA Transposable Elements; 0 / DNA, Bacterial; 72909-34-3 / PQQ Cofactor; EC 1.1.1.- / Glucose Dehydrogenases; EC 1.1.5.2 / glucose dehydrogenase (pyrroloquinoline-quinone)
  • [Other-IDs] NLM/ PMC2772458
  •  go-up   go-down


89. Linguraru MG, Yao J, Gautam R, Peterson J, Li Z, Linehan WM, Summers RM: Renal Tumor Quantification and Classification in Contrast-Enhanced Abdominal CT. Pattern Recognit; 2009 Jun 01;42(6):1149-1161
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal Tumor Quantification and Classification in Contrast-Enhanced Abdominal CT.
  • It is estimated that almost a quarter of a million people in the USA are living with kidney cancer and their number increases with 51,000 diagnosed with the disease every year.
  • In clinical practice, the response to treatment is monitored by manual measurements of tumor size, which are 2D, do not reflect the 3D geometry and enhancement of tumors, and show high intra- and inter-operator variability.
  • We propose a computer-assisted radiology tool to assess renal tumors in contrast-enhanced CT for the management of tumor diagnoses and responses to new treatments.
  • Tumors are robustly segmented and the comparison between manual and semi-automated quantifications shows disparity within the limits of inter-observer variability.
  • The analysis of lesion enhancement for tumor classification shows great separation between cysts, von Hippel-Lindau syndrome lesions and hereditary papillary renal carcinomas (HPRC) with p-values inferior to 0.004.
  • The results on temporal evaluation of tumors from serial scans illustrate the potential of the method to become an important tool for disease monitoring, drug trials and noninvasive clinical surveillance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest Radiol. 1998 Jun;33(6):348-55 [9647447.001]
  • [Cites] J Urol. 2005 May;173(5):1482-6 [15821464.001]
  • [Cites] Nat Clin Pract Urol. 2005 May;2(5):248-55 [16474836.001]
  • [Cites] Radiology. 2007 Sep;244(3):767-75 [17709828.001]
  • [Cites] IEEE Trans Med Imaging. 2003 Apr;22(4):483-92 [12774894.001]
  • [Cites] Int J Med Robot. 2006 Mar;2(1):91-7 [17520618.001]
  • [Cites] Med Image Comput Comput Assist Interv. 2006;9(Pt 2):758-65 [17354841.001]
  • [Cites] Acta Radiol. 2004 Nov;45(7):791-5 [15624525.001]
  • [Cites] Med Image Anal. 2006 Dec;10 (6):850-62 [16945569.001]
  • [Cites] BJU Int. 2005 Mar;95 Suppl 2:2-7 [15720328.001]
  • [Cites] Acad Radiol. 2006 Oct;13(10 ):1254-65 [16979075.001]
  • [Cites] J Comput Assist Tomogr. 2007 Jan-Feb;31(1):37-41 [17259831.001]
  • [Cites] Med Image Anal. 1998 Sep;2(3):243-60 [9873902.001]
  • [Cites] IEEE Trans Med Imaging. 2003 Jan;22(1):120-8 [12703765.001]
  • [Cites] Nat Rev Cancer. 2005 Jul;5(7):516-25 [15965493.001]
  • [Cites] Am J Hum Genet. 2005 Jun;76(6):1023-33 [15852235.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1256-61 [15371818.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):667s-670s [17255291.001]
  • [Cites] Abdom Imaging. 2000 May-Jun;25(3):317-21 [10823459.001]
  • [Cites] Med Phys. 2004 Mar;31(3):427-32 [15070239.001]
  • [Cites] Lab Invest. 1998 May;78(5):511-22 [9605176.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2163-72 [14634372.001]
  • [Cites] Comput Aided Surg. 2006 May;11(3):119-25 [16829505.001]
  • [Cites] Magn Reson Med. 2007 Jun;57(6):1159-67 [17534915.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):223-8 [15380513.001]
  • [Cites] Radiology. 2007 Aug;244(2):494-504 [17641370.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):954-60 [15708280.001]
  • [Cites] Eur Radiol. 2006 Jun;16(6):1244-52 [16404565.001]
  • [Cites] Eur J Radiol. 2007 Sep;63(3):420-6 [17367973.001]
  • [Cites] Lancet Oncol. 2007 Nov;8(11):956-7 [17976606.001]
  • [Cites] IEEE Trans Med Imaging. 2002 May;21(5):538-50 [12071624.001]
  • [Cites] Comput Aided Surg. 2006 May;11(3):127-36 [16829506.001]
  • (PMID = 19492069.001).
  • [ISSN] 0031-3203
  • [Journal-full-title] Pattern recognition
  • [ISO-abbreviation] Pattern Recognit
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 SC006659-25; United States / Intramural NIH HHS / / Z99 CL999999
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


90. Shibata Y: Boron distribution in the normal rat brain after intravenous injection of boronophenylalanine-fructose. J Neurooncol; 2008 Mar;87(1):35-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Boron neutron capture therapy (BNCT) is an experimental form of radiation therapy for malignant brain tumors and peripheral melanoma.
  • The micro-distribution of the boron compound is critical to determine the radiation effects for both tumors and normal tissue.

  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • Hazardous Substances Data Bank. BORON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Jun;82(11):1764-71 [10839288.001]
  • [Cites] Radiat Res. 1998 Feb;149(2):163-70 [9457896.001]
  • [Cites] Strahlenther Onkol. 1989 Feb-Mar;165(2-3):188-92 [2494725.001]
  • [Cites] Neurosurgery. 1998 Mar;42(3):463-8; discussion 468-9 [9526978.001]
  • [Cites] Radiat Res. 1999 Jan;151(1):1-18 [9973079.001]
  • [Cites] Stereotact Funct Neurosurg. 1995;64 Suppl 1:233-8 [8584833.001]
  • [Cites] J Nucl Med. 1986 May;27(5):677-84 [3712083.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(1):27-39 [1572828.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):3987-4002 [15930333.001]
  • [Cites] Radiat Res. 1995 Oct;144(1):50-8 [7568771.001]
  • [Cites] J Clin Endocrinol Metab. 1982 Jun;54(6):1135-9 [7042731.001]
  • [Cites] Radiother Oncol. 1994 Sep;32(3):249-55 [7816943.001]
  • [Cites] Radiat Res. 1994 Oct;140(1):72-8 [7938457.001]
  • [Cites] J Appl Physiol (1985). 1998 Sep;85(3):1024-9 [9729579.001]
  • [Cites] Phys Med Biol. 1993 Aug;38(8):1089-97 [8367521.001]
  • [Cites] J Neurosurg. 1982 Jun;56(6):826-9 [7077383.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):43-50 [9420071.001]
  • [Cites] J Neurosurg. 2005 Dec;103(6):1000-9 [16381186.001]
  • [Cites] Br J Cancer. 1993 Apr;67(4):701-5 [8471428.001]
  • [Cites] Am J Physiol. 1978 Jan;234(1):H59-66 [623275.001]
  • [Cites] Am J Physiol. 1982 Jan;242(1):E1-11 [7058882.001]
  • [Cites] Anal Chem. 1997 Aug 15;69(16):3169-76 [9271061.001]
  • [Cites] Magn Reson Med. 1991 Nov;22(1):32-46 [1798393.001]
  • [Cites] Cell Tissue Res. 1975;156(4):451-61 [164285.001]
  • [Cites] J Nucl Med. 1998 Feb;39(2):325-33 [9476945.001]
  • [Cites] Radiat Res. 2000 Feb;153(2):173-80 [10629616.001]
  • [Cites] Cancer Res. 1990 Jan 1;50(1):138-41 [2293547.001]
  • [Cites] Cancer Res. 1987 Oct 15;47(20):5451-4 [3652047.001]
  • [Cites] Med Biol. 1975 Apr;53(2):114-20 [1080229.001]
  • [Cites] J Endocrinol. 2001 Jun;169(3):519-26 [11375122.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Mar 30;28(5):1183-8 [8175404.001]
  • [Cites] Radiat Res. 1998 Apr;149(4):378-86 [9525503.001]
  • [Cites] Ann Neurol. 1982 May;11(5):499-502 [7103426.001]
  • [Cites] J Neural Transm. 1979;46(3):183-93 [528993.001]
  • [Cites] Acta Radiol Oncol. 1982;21(1):49-60 [6283797.001]
  • [Cites] J Neurooncol. 1997 May;33(1-2):81-92 [9151226.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1995 Jan;36(1):247-51 [7822153.001]
  • [Cites] Brain. 1981 Jun;104(2):319-32 [7237097.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 30;27(2):215-21 [8407394.001]
  • [Cites] J Biol Chem. 1988 Dec 25;263(36):19392-7 [2848825.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):1846-50 [7892189.001]
  • [Cites] Brain Res. 1981 Dec 28;230(1-2):165-79 [7317777.001]
  • [Cites] J Nutr. 1984 May;114(5):835-9 [6726452.001]
  • [Cites] Cancer Res. 1995 Feb 15;55(4):874-7 [7850802.001]
  • [Cites] Strahlenther Onkol. 1989 Feb-Mar;165(2-3):127-9 [2928932.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):597-602 [10837941.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Mar;70(3):814-6 [2307734.001]
  • [Cites] Proc Soc Exp Biol Med. 1971 Apr;136(4):1115-8 [5554455.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4302-6 [8813111.001]
  • [Cites] Anesth Analg. 1995 Apr;80(4):687-95 [7893019.001]
  • (PMID = 18026910.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boron Compounds; 30237-26-4 / Fructose; 47E5O17Y3R / Phenylalanine; N9E3X5056Q / Boron
  •  go-up   go-down


91. Sersa G, Kranjc S, Scancar J, Krzan M, Cemazar M: Electrochemotherapy of mouse sarcoma tumors using electric pulse trains with repetition frequencies of 1 Hz and 5 kHz. J Membr Biol; 2010 Jul;236(1):155-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electrochemotherapy of mouse sarcoma tumors using electric pulse trains with repetition frequencies of 1 Hz and 5 kHz.
  • Electrochemotherapy is an efficient local treatment of tumors that combines administration of a chemotherapeutic drug with the subsequent application of electric pulses to the tumor.
  • Although no difference in clinical response of the treated tumors to the electrochemotherapy when using 1 Hz or 5 kHz repetition frequency was observed, it is mandatory to be aware of possible differences in the effectiveness of electrochemotherapy when using suboptimal doses of the drugs.
  • Electrochemotherapy of fibrosarcoma SA-1 subcutaneous tumors transplanted in A/J mice resulted in good antitumor effectiveness, but antitumor effectiveness was significantly better at 1 Hz repetition frequency than at 5 kHz.
  • The platinum content was higher in tumors treated with a 1 Hz repetition frequency.
  • The application of electric pulses to the tumors at a 5 kHz repetition frequency induced an immediate reduction in tumor perfusion, comparable to the reduction at 1 Hz but with faster reperfusion.
  • The greater effectiveness of electrochemotherapy using electric pulse trains of 1 Hz compared to 5 kHz is due to the greater electroporative effect and longer time in which electroporated tumors are exposed to the two chemotherapeutic drugs.
  • [MeSH-minor] Animals. Bleomycin / pharmacology. Cisplatin / pharmacology. Dose-Response Relationship, Drug. Female. Male. Mice. Neoplasm Transplantation

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1386-91 [10188880.001]
  • [Cites] Anticancer Drugs. 1998 Jul;9(6):525-30 [9877240.001]
  • [Cites] Bioelectrochemistry. 2002 Sep;57(2):167-72 [12160614.001]
  • [Cites] Br J Cancer. 2008 Jan 29;98(2):388-98 [18182988.001]
  • [Cites] Biochim Biophys Acta. 1994 Feb 23;1190(1):155-63 [7509192.001]
  • [Cites] Bioelectrochemistry. 2005 Feb;65(2):121-8 [15713562.001]
  • [Cites] Eur J Cancer. 1999 Apr;35(4):672-7 [10492645.001]
  • [Cites] Ann Surg Oncol. 2008 Aug;15(8):2215-22 [18498012.001]
  • [Cites] Neoplasma. 2007;54(3):246-50 [17447858.001]
  • [Cites] Ann Surg Oncol. 2009 Jan;16(1):191-9 [18987914.001]
  • [Cites] Eur J Surg Oncol. 2008 Feb;34(2):232-40 [17614247.001]
  • [Cites] Bioelectrochemistry. 2005 Feb;65(2):105-11 [15713560.001]
  • [Cites] Biochim Biophys Acta. 1997 Feb 11;1334(1):9-14 [9042358.001]
  • [Cites] Biophys J. 1998 May;74(5):2152-8 [9591642.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1731-6 [12168862.001]
  • [Cites] Ann Surg. 2007 Mar;245(3):469-79 [17435555.001]
  • [Cites] J Pharm Biomed Anal. 1997 Oct;16(2):343-8 [9408853.001]
  • [Cites] Biochim Biophys Acta. 2002 Jan 15;1569(1-3):51-8 [11853957.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 27;1473(2-3):321-8 [10594369.001]
  • [Cites] Anticancer Res. 1999 Sep-Oct;19(5B):4017-22 [10628347.001]
  • [Cites] Croat Med J. 2007 Jun;48(3):391-5 [17589984.001]
  • [Cites] Eur J Cancer. 1991;27(1):68-72 [1707289.001]
  • [Cites] Acta Physiol Scand. 2003 Apr;177(4):437-47 [12648161.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 May;6(5):671-8 [16759159.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3450-5 [7614485.001]
  • [Cites] Bioelectrochem Bioenerg. 1999 Feb;48(1):17-25 [10228566.001]
  • [Cites] EMBO J. 1982;1(7):841-5 [6329708.001]
  • [Cites] Br J Cancer. 1998 Jun;77(12):2104-11 [9649121.001]
  • (PMID = 20607223.001).
  • [ISSN] 1432-1424
  • [Journal-full-title] The Journal of membrane biology
  • [ISO-abbreviation] J. Membr. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


92. Karayan-Tapon L, Quillien V, Guilhot J, Wager M, Fromont G, Saikali S, Etcheverry A, Hamlat A, Loussouarn D, Campion L, Campone M, Vallette FM, Gratas-Rabbia-Ré C: Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. J Neurooncol; 2010 May;97(3):311-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eighty-one tumors were obtained from patients with glioblastomas treated by surgery and radiotherapy with concomitant temozolomide (TMZ) followed by adjuvant TMZ.
  • [MeSH-major] DNA Modification Methylases / metabolism. DNA Repair Enzymes / metabolism. Glioblastoma / diagnosis. Glioblastoma / enzymology. Tumor Suppressor Proteins / metabolism


93. Brunner K, Fischer CA, Driemel O, Hartmann A, Brockhoff G, Schwarz S: EGFR (HER) family protein expression and cytogenetics in 219 squamous cell carcinomas of the upper respiratory tract: ERBB2 overexpression independent prediction of poor prognosis. Anal Quant Cytol Histol; 2010 Apr;32(2):78-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: High expression of HER1 and HER2 was present in 49.4% and 6.6% of tumors, respectively.
  • A gene amplification of HER1 occurred in 5.2% of tumors, whereas none of the tumors showed an amplification of HER2-4 loci.
  • In univariate overall survival analysis a negative prognostic impact could be demonstrated for high expression of HER2 (p < 0.01), advanced local tumor growth (p < 0.01), lymph node metastasis (p < 0.01), presence of residual tumor after surgical therapy (p < 0.01), high proliferative activity (Ki-67; p = 0.02) and high chromosomal instability (p = 0.01).
  • According to the multivariate analysis, the strongest negative predictors of survival were advanced tumor growth (p < 0.01), presence of residual tumor (p < 0.01), high expression of HER2 (p < 0.01) and chromosomal instability (p = 0.03).
  • CONCLUSION: Overexpression of HER2 and presence of chromosomal instability harbor an additional prognostic impact on disease-specific survival and prove to be independent negative prognostic factors in head and neck squamous cell carcinomas.


9
Advertisement
4. Sawai T, Uzuki M, Kamataki A, Tofukuji I: The state of telepathology in Japan. J Pathol Inform; 2010;1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Telepathology in Japan is most often used for rapid intraoperative pathological diagnosis using frozen section, followed by second opinions and consultation.
  • Intraoperatively, telepathology is used to determine malignancy, metastasis of malignant tumors, and the extent of excision.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20922030.001).
  • [ISSN] 2153-3539
  • [Journal-full-title] Journal of pathology informatics
  • [ISO-abbreviation] J Pathol Inform
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2941966
  • [Keywords] NOTNLM ; Japan / telepathology
  •  go-up   go-down


95. Lim ST, Levine AM: Non-AIDS-defining cancers and HIV infection. Curr HIV/AIDS Rep; 2005 Aug;2(3):146-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These include Hodgkin's disease, anal carcinoma, lung cancer, nonmelanomatous skin cancer, and testicular germ cell tumors, among others.
  • [MeSH-major] HIV Infections / complications. Immunosuppression / adverse effects. Neoplasms / etiology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 [12679705.001]
  • [Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]
  • [Cites] Eur J Epidemiol. 1995 Dec;11(6):609-14 [8861842.001]
  • [Cites] Ann Thorac Surg. 2003 Feb;75(2):367-71 [12607641.001]
  • [Cites] J Acquir Immune Defic Syndr. 2000 Aug 15;24(5):444-50 [11035615.001]
  • [Cites] Hematol Oncol Clin North Am. 1991 Apr;5(2):343-56 [2022598.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Natl Cancer Inst. 1997 Nov 5;89(21):1602-8 [9362158.001]
  • [Cites] AIDS. 2003 Feb 14;17(3):371-5 [12556691.001]
  • [Cites] AIDS Care. 1996 Feb;8(1):5-14 [8664369.001]
  • [Cites] Ann Oncol. 1993 Sep;4(8):635-41 [8240994.001]
  • [Cites] J Clin Oncol. 1995 Oct;13(10):2540-6 [7595705.001]
  • [Cites] Eur J Cancer. 2001 Jul;37(10):1276-87 [11423259.001]
  • [Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]
  • [Cites] J Clin Oncol. 1995 Nov;13(11):2705-11 [7595728.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2739-45 [11753946.001]
  • [Cites] Int J STD AIDS. 2001 Feb;12(2):100-2 [11236097.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1984-8 [12200356.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]
  • [Cites] AIDS. 2001 Nov 9;15(16):2157-64 [11684935.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):432-6 [1617592.001]
  • [Cites] Cancer. 1990 May 15;65(10):2248-54 [2346909.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Ann Oncol. 1999 Feb;10(2):189-95 [10093688.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):563-9 [10649248.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1562-9 [14504059.001]
  • [Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]
  • [Cites] Ann Intern Med. 2003 Mar 18;138(6):453-9 [12639077.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1391-7 [7538557.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1348-9; author reply 1349-50 [15051794.001]
  • [Cites] Clin Infect Dis. 2003 Jul 15;37(2):292-8 [12856222.001]
  • [Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):480-8 [10950375.001]
  • [Cites] Hematol Oncol Clin North Am. 1996 Oct;10(5):997-1010 [8880192.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):966-70 [9764592.001]
  • [Cites] Chest. 1993 Feb;103(2):410-3 [8432128.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Sep;11(9):1587-93 [3928544.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2319-26 [10090942.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12667-71 [11058153.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] Chest. 1998 Jan;113(1):154-61 [9440583.001]
  • [Cites] Mutat Res. 1999 Oct 19;429(2):249-59 [10526209.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):754-8 [10762748.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):1922-7 [12743144.001]
  • [Cites] Fundam Appl Toxicol. 1996 Aug;32(2):148-58 [8921318.001]
  • [Cites] Mutagenesis. 2000 Sep;15(5):405-10 [10970446.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):753-7 [11745473.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:201-5 [1710920.001]
  • [Cites] Lung Cancer. 2002 Apr;36(1):9-14 [11891027.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):457-9 [12888811.001]
  • [Cites] Am J Surg Pathol. 1996 Dec;20(12):1520-4 [8944046.001]
  • [Cites] Chest. 1992 Dec;102(6):1704-8 [1446476.001]
  • (PMID = 16091262.001).
  • [ISSN] 1548-3568
  • [Journal-full-title] Current HIV/AIDS reports
  • [ISO-abbreviation] Curr HIV/AIDS Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 64
  •  go-up   go-down


96. Castro NP, Osório CA, Torres C, Bastos EP, Mourão-Neto M, Soares FA, Brentani HP, Carraro DM: Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Breast Cancer Res; 2008;10(5):R87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Ductal carcinoma in situ (DCIS) of the breast includes a heterogeneous group of preinvasive tumors with uncertain evolution.
  • Definition of the molecular factors necessary for progression to invasive disease is crucial to determining which lesions are likely to become invasive.
  • RESULTS: Among the tumor sample groups, cells from pure DCIS exhibited the most divergent molecular profile, consequently identifying cells from in situ component of lesions with co-existing invasive ductal carcinoma as very similar to cells from invasive lesions.
  • Among these genes, LOX and SULF-1 exhibited features that identify them as potential participants in the malignant process of DCIS.
  • CONCLUSIONS: We identified new genes that are potentially involved in the malignant transformation of DCIS, and our findings strongly suggest that cells from the in situ component of lesions with co-existing invasive ductal carcinoma exhibit molecular alterations that enable them to invade the surrounding tissue before morphological changes in the lesion become apparent.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Gene Expression Profiling. Genes, Neoplasm. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Microdissection. Middle Aged. Neoplasm Invasiveness / genetics. Oligonucleotide Array Sequence Analysis. Protein-Lysine 6-Oxidase / genetics. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. RNA, Neoplasm / biosynthesis. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction. Sulfotransferases / genetics. Time Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hum Genet. 1999;44(6):383-7 [10570909.001]
  • [Cites] Anal Biochem. 2003 Oct 15;321(2):244-51 [14511690.001]
  • [Cites] Endocr Relat Cancer. 2001 Mar;8(1):47-61 [11350726.001]
  • [Cites] CMAJ. 2001 Oct 2;165(7):912-3 [11599333.001]
  • [Cites] J Natl Cancer Inst. 2001 Dec 5;93(23):1811-7 [11734598.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Nucleic Acids Res. 2002 Feb 15;30(4):e15 [11842121.001]
  • [Cites] J Pathol. 2002 Mar;196(3):280-6 [11857490.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Biotechniques. 2003 Feb;34(2):374-8 [12613259.001]
  • [Cites] Mol Cancer Res. 2003 Mar;1(5):362-75 [12651909.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9 [12714683.001]
  • [Cites] Oncogene. 2003 Jun 12;22(24):3742-8 [12802281.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3A):2043-51 [12894577.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 [12917485.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3A):1719-23 [16033090.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11429-36 [16357151.001]
  • [Cites] Oncogene. 2006 Apr 13;25(16):2328-38 [16314837.001]
  • [Cites] Jpn J Clin Oncol. 2003 Nov;33(11):556-62 [14711979.001]
  • [Cites] Oncogene. 2004 Feb 19;23(7):1439-47 [14973553.001]
  • [Cites] N Engl J Med. 2004 Apr 1;350(14):1430-41 [15070793.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5160-7 [15297420.001]
  • [Cites] Nat Genet. 2004 Sep;36(9):984-8 [15300252.001]
  • [Cites] Int J Oncol. 2004 Oct;25(4):797-819 [15375528.001]
  • [Cites] Cancer. 1989 Nov 1;64(9):1914-21 [2551477.001]
  • [Cites] Differentiation. 1991 Apr;46(3):209-21 [1833254.001]
  • [Cites] Am J Clin Pathol. 1994 Mar;101(3):262-5 [8135179.001]
  • [Cites] Cancer Res. 1995 Feb 1;55(3):467-71 [7834608.001]
  • [Cites] Lab Invest. 2005 Jan;85(1):154-9 [15543203.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 May;54(2):95-105 [15843092.001]
  • [Cites] Nature. 2006 Apr 27;440(7088):1222-6 [16642001.001]
  • [Cites] Histopathology. 2006 May;48(6):702-7 [16681686.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5278-86 [16707453.001]
  • [Cites] Cell. 2006 Jun 30;125(7):1269-81 [16814714.001]
  • [Cites] Cell. 2006 Nov 17;127(4):679-95 [17110329.001]
  • [Cites] Breast Cancer Res. 2006;8(5):R61 [17069663.001]
  • [Cites] Hum Pathol. 2007 Feb;38(2):197-204 [17234468.001]
  • [Cites] PLoS One. 2007;2(4):e392 [17460759.001]
  • [Cites] J Biol Chem. 2007 May 11;282(19):14413-20 [17363371.001]
  • [Cites] Ann Clin Lab Sci. 2007 Spring;37(2):127-34 [17522367.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Jun;292(6):C2288-96 [17329398.001]
  • [Cites] EMBO J. 2007 Jul 25;26(14):3410-22 [17599062.001]
  • [Cites] BMC Bioinformatics. 2007;8:291 [17683614.001]
  • [Cites] J Cell Biochem. 2008 Apr 1;103(5):1369-78 [17685448.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • (PMID = 18928525.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 1.4.3.13 / Protein-Lysine 6-Oxidase; EC 2.8.2.- / SULF1 protein, human; EC 2.8.2.- / Sulfotransferases
  • [Other-IDs] NLM/ PMC2614523
  •  go-up   go-down


97. Yin Z, Williams-Simons L, Parlow AF, Asa S, Kirschner LS: Pituitary-specific knockout of the Carney complex gene Prkar1a leads to pituitary tumorigenesis. Mol Endocrinol; 2008 Feb;22(2):380-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carney complex (CNC) is an inherited neoplasia syndrome characterized by spotty skin pigmentation, myxomas, endocrine tumors, and schwannomas.
  • Among the endocrine tumors that comprise the syndrome, GH-producing pituitary tumors are seen in approximately 10% of patients, although biochemical abnormalities of the GH axis are much more common.
  • Although prolactinomas were observed in KO and control mice, the KO mice exhibited a significantly increased frequency of pituitary tumors compared with wild-type or conventional Prkar1a(+/-) mice.
  • Characterization of the tumors demonstrated they were composed of cells of the Pit1 lineage that stained for GH, prolactin, and TSH.
  • At the biochemical level, levels of GH in the serum of KO animals were markedly elevated compared with controls, regardless of the presence of a frank tumor.
  • These data indicate that complete loss of Prkar1a is sufficient to allow the formation of pituitary tumors and abnormalities of the GH axis, in close analogy to human patients with CNC.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2003 Sep;23(17):6075-85 [12917331.001]
  • [Cites] Oncogene. 2004 Jan 29;23(4):905-13 [14647411.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):285-95 [15057288.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):613-9 [15274075.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14222-7 [15371594.001]
  • [Cites] Ann N Y Acad Sci. 1989;553:191-6 [2497671.001]
  • [Cites] Nature. 1989 Aug 31;340(6236):692-6 [2549426.001]
  • [Cites] N Engl J Med. 1991 Dec 12;325(24):1688-95 [1944469.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):295-300 [1406933.001]
  • [Cites] Horm Res. 1992;38(1-2):90-3 [1306524.001]
  • [Cites] Endocrinology. 1995 Sep;136(9):4147-50 [7649123.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10655-60 [9724759.001]
  • [Cites] Genes Dev. 1998 Sep 15;12(18):2899-911 [9744866.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):70-1 [9916792.001]
  • [Cites] Dev Biol. 1999 Apr 15;208(2):281-92 [10191045.001]
  • [Cites] Endocrinology. 1999 Nov;140(11):5348-55 [10537166.001]
  • [Cites] Oncogene. 2000 Apr 6;19(15):1875-84 [10773877.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):89-92 [10973256.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Oct;85(10):3860-5 [11061550.001]
  • [Cites] Genesis. 2000 Nov-Dec;28(3-4):167-74 [11105060.001]
  • [Cites] Brain Pathol. 2001 Jul;11(3):371-84 [11414478.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4041-6 [11549623.001]
  • [Cites] Endocr Rev. 2001 Oct;22(5):675-705 [11588148.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71 [11739416.001]
  • [Cites] Genome Biol. 2001;2(12):REVIEWS3013 [11790261.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Oct;57(4):443-8 [12354125.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):836-49 [12415254.001]
  • [Cites] J Med Genet. 2002 Dec;39(12):e78 [12471216.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Apr;58(4):464-70 [12641630.001]
  • [Cites] Anal Biochem. 1999 Jun 1;270(2):334-6 [10334853.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9193-8 [15604292.001]
  • [Cites] Pituitary. 2004;7(2):73-82 [15761655.001]
  • [Cites] Pituitary. 2004;7(2):95-101 [15761658.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3846-52 [15867383.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4506-14 [15930266.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Dec;90(12):6721-4 [16204369.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Sep;91(9):3316-23 [16787992.001]
  • [Cites] Endocrinology. 2007 May;148(5):1946-53 [17289844.001]
  • [Cites] Mol Endocrinol. 2007 Aug;21(8):1969-83 [17536003.001]
  • [Cites] Genesis. 2008 Jan;46(1):37-42 [18196598.001]
  • (PMID = 17975024.001).
  • [ISSN] 0888-8809
  • [Journal-full-title] Molecular endocrinology (Baltimore, Md.)
  • [ISO-abbreviation] Mol. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016058; United States / NCI NIH HHS / CA / R01 CA112268; United States / NCI NIH HHS / CA / CA 112268; United States / NCI NIH HHS / CA / CA 16058
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclic AMP-Dependent Protein Kinase RIalpha Subunit; 0 / Prkar1a protein, mouse; 9002-62-4 / Prolactin; 9002-71-5 / Thyrotropin; 9002-72-6 / Growth Hormone; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
  • [Other-IDs] NLM/ PMC2234591
  •  go-up   go-down


98. Lo Muzio L, Santoro A, Pieramici T, Bufo P, Di Alberti L, Mazzotta P, Mazzotta A, Carinci F, Rubini C, Lo Russo L: Immunohistochemical expression of CD3, CD20, CD45, CD68 and bcl-2 in oral squamous cell carcinoma. Anal Quant Cytol Histol; 2010 Apr;32(2):70-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A trend was observed for the association of inflammatory infiltrate with the degree of tumor differentiation: well and moderately differentiated tumors tend to be associated to a dense inflammatory infiltrate (57.9% of cases), while poorly differentiated cancers seem to be associated to a low inflammatory infiltrate in 85.7% of cases.


99. Barth BM, Sharma R, Altinoğlu EI, Morgan TT, Shanmugavelandy SS, Kaiser JM, McGovern C, Matters GL, Smith JP, Kester M, Adair JH: Bioconjugation of calcium phosphosilicate composite nanoparticles for selective targeting of human breast and pancreatic cancers in vivo. ACS Nano; 2010 Mar 23;4(3):1279-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The early diagnosis of cancer is the critical element in successful treatment and long-term favorable patient prognoses.
  • The high rate of mortality is mainly attributed to the tendency for late diagnoses as symptoms may not occur until the disease has metastasized, as well as the lack of effective systemic therapies.
  • Late diagnosis is often associated with the lack of timely sensitive imaging modalities.
  • These bioconjugated CPNPs have the potential to perform as a theranostic modality, simultaneously enhancing drug delivery, targeting, and imaging of breast and pancreatic cancer tumors.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Physiol. 2001;63:49-76 [11181948.001]
  • [Cites] Pancreas. 2009 Jul;38(5):e151-61 [19465883.001]
  • [Cites] Regul Pept. 2004 Mar 15;117(3):167-73 [14749036.001]
  • [Cites] Nature. 1980 Aug 28;286(5776):888-91 [7412870.001]
  • [Cites] Int J Cancer. 1981 Mar 15;27(3):329-34 [6270015.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Jul;78(7):4515-9 [6270680.001]
  • [Cites] Anal Biochem. 1985 Nov 15;151(1):178-81 [4091277.001]
  • [Cites] J Biol Chem. 1988 Apr 15;263(11):5341-7 [3356689.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3605-9 [1373504.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8691-5 [1528881.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5076-80 [8506353.001]
  • [Cites] Am J Physiol. 1994 Jan;266(1 Pt 2):R277-83 [8304551.001]
  • [Cites] Am J Physiol. 1995 Jan;268(1 Pt 2):R135-41 [7840313.001]
  • [Cites] Am J Physiol. 1996 May;270(5 Pt 2):R1078-84 [8928909.001]
  • [Cites] Biochem J. 1996 May 15;316 ( Pt 1):193-9 [8645205.001]
  • [Cites] Am J Physiol. 1996 Sep;271(3 Pt 2):R797-805 [8853405.001]
  • [Cites] Int J Oncol. 1998 Feb;12(2):411-9 [9458369.001]
  • [Cites] J Cereb Blood Flow Metab. 2004 Nov;24(11):1193-204 [15545912.001]
  • [Cites] Nature. 2006 May 25;441(7092):537-41 [16724069.001]
  • [Cites] Clin Immunol. 2006 Nov;121(2):144-58 [16904380.001]
  • [Cites] Clin Immunol. 2006 Nov;121(2):159-76 [16920030.001]
  • [Cites] Eur J Pharm Sci. 2007 Jun;31(2):102-11 [17387005.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Int J Nanomedicine. 2008;3(1):21-9 [18488413.001]
  • [Cites] ACS Nano. 2008 Oct 28;2(10):2075-84 [19206454.001]
  • [Cites] Mol Cancer Ther. 2009 Mar;8(3):648-54 [19276162.001]
  • [Cites] Nano Lett. 2009 Apr;9(4):1559-66 [19260707.001]
  • [Cites] Nano Lett. 2008 Dec;8(12):4108-15 [19367837.001]
  • [Cites] Nano Lett. 2008 Dec;8(12):4116-21 [19367878.001]
  • [Cites] Int J Mol Med. 2002 Dec;10(6):689-94 [12429993.001]
  • (PMID = 20180585.001).
  • [ISSN] 1936-086X
  • [Journal-full-title] ACS nano
  • [ISO-abbreviation] ACS Nano
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA117926-03; United States / NCI NIH HHS / CA / R01 CA117926; United States / NCI NIH HHS / CA / R01 CA117926-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptor, Cholecystokinin B; 0 / Silicates
  • [Other-IDs] NLM/ NIHMS182611; NLM/ PMC2894697
  •  go-up   go-down


100. Bereman MS, Williams TI, Muddiman DC: Development of a nanoLC LTQ orbitrap mass spectrometric method for profiling glycans derived from plasma from healthy, benign tumor control, and epithelial ovarian cancer patients. Anal Chem; 2009 Feb 1;81(3):1130-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a nanoLC LTQ orbitrap mass spectrometric method for profiling glycans derived from plasma from healthy, benign tumor control, and epithelial ovarian cancer patients.
  • In addition, data are compared among samples derived from 10 healthy controls, 10 controls with a differential diagnosis of benign gynecologic tumors, and 10 diseased epithelial ovarian cancer patients (EOC).
  • However, these same glycans provided a significantly less diagnostic value when used to differentiate EOC from benign tumor control samples with an area under the curve of 0.73.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma / diagnosis. Chromatography, Liquid / methods. Glycoproteins / blood. Ovarian Neoplasms / diagnosis. Polysaccharides / blood. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods
  • [MeSH-minor] Female. Genital Neoplasms, Female / chemistry. Genital Neoplasms, Female / diagnosis. Humans. Hydrophobic and Hydrophilic Interactions. Lectins / blood. Lectins / chemistry. Male. ROC Curve

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):4-8 [10580125.001]
  • [Cites] Anal Chem. 2008 Oct 1;80(19):7534-42 [18778038.001]
  • [Cites] Fresenius J Anal Chem. 2000 Mar-Apr;366(6-7):669-76 [11225778.001]
  • [Cites] Biochem J. 2001 Jul 1;357(Pt 1):167-82 [11415447.001]
  • [Cites] Rapid Commun Mass Spectrom. 2001;15(19):1862-8 [11565105.001]
  • [Cites] J Am Soc Mass Spectrom. 2002 Apr;13(4):402-7 [11951978.001]
  • [Cites] Cancer Metastasis Rev. 2001;20(3-4):245-77 [12085965.001]
  • [Cites] Rapid Commun Mass Spectrom. 2002;16(13):1320-9 [12112260.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10231-3 [12149519.001]
  • [Cites] J Chromatogr A. 2002 Aug 30;968(1-2):89-100 [12236519.001]
  • [Cites] Anal Biochem. 2003 May 1;316(1):15-22 [12694722.001]
  • [Cites] Clin Exp Metastasis. 2003;20(2):143-52 [12705635.001]
  • [Cites] J Biol Chem. 2003 Aug 1;278(31):28619-34 [12734200.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):45-60 [14681689.001]
  • [Cites] Anal Chem. 2004 Feb 1;76(3):833-8 [14750882.001]
  • [Cites] Mass Spectrom Rev. 2004 May-Jun;23(3):161-227 [14966796.001]
  • [Cites] Rapid Commun Mass Spectrom. 2004;18(19):2282-92 [15384149.001]
  • [Cites] J Natl Cancer Inst. 1978 Oct;61(4):961-5 [309009.001]
  • [Cites] J Chromatogr. 1979 Apr 11;162(4):507-28 [528665.001]
  • [Cites] Anal Biochem. 1982 Jan 15;119(2):351-9 [7041698.001]
  • [Cites] Anal Chem. 1990 Feb 1;62(3):248-52 [2305955.001]
  • [Cites] J Chromatogr. 1990 Jan 19;499:177-96 [2324207.001]
  • [Cites] Methods Enzymol. 1990;193:647-60 [2074840.001]
  • [Cites] J Chromatogr. 1993 Sep 3;646(2):317-26 [8408434.001]
  • [Cites] Anal Chem. 1996 Sep 15;68(18):3215-23 [8797382.001]
  • [Cites] Anal Chem. 1997 Nov 15;69(22):4530-5 [9375514.001]
  • [Cites] Anal Chem. 1998 Dec 1;70(23):4951-9 [9852781.001]
  • [Cites] Bioessays. 1999 May;21(5):412-21 [10376012.001]
  • [Cites] Biochemistry. 1964 Jan;3:113-20 [14114492.001]
  • [Cites] Anal Chem. 2005 Feb 1;77(3):886-94 [15679358.001]
  • [Cites] Glycobiology. 2005 Dec;15(12):1332-40 [16037490.001]
  • [Cites] Mol Cell Proteomics. 2005 Dec;4(12):2010-21 [16249172.001]
  • [Cites] Proteomics. 2005 Dec;5(18):4665-72 [16281179.001]
  • [Cites] Glycobiology. 2006 Feb;16(2):132-45 [16177264.001]
  • [Cites] J Chromatogr A. 2006 Jan 27;1103(2):296-306 [16364349.001]
  • [Cites] J Proteome Res. 2006 Jul;5(7):1626-35 [16823970.001]
  • [Cites] Mol Cell Proteomics. 2007 Jan;6(1):43-55 [16847285.001]
  • [Cites] Rapid Commun Mass Spectrom. 2007;21(5):807-11 [17279479.001]
  • [Cites] Anal Chem. 2007 Jul 1;79(13):5051-7 [17539604.001]
  • [Cites] J Proteome Res. 2007 Aug;6(8):2936-62 [17583933.001]
  • [Cites] Biochemistry. 2008 Mar 11;47(10):3155-61 [18260648.001]
  • [Cites] J Proteome Res. 2008 Mar;7(3):1109-17 [18237112.001]
  • [Cites] Proteomics. 2008 Apr;8(7):1384-97 [18318007.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1650-9 [18311910.001]
  • [Cites] Anal Bioanal Chem. 2008 May;391(1):289-97 [18327675.001]
  • [Cites] J Proteome Res. 2008 Jun;7(6):2562-8 [18422354.001]
  • [Cites] Clin Chem. 2008 Jul;54(7):1166-75 [18487288.001]
  • [Cites] Anal Chem. 2008 Aug 1;80(15):6119-26 [18593198.001]
  • [Cites] J Am Soc Mass Spectrom. 2008 Aug;19(8):1138-46 [18511294.001]
  • [Cites] J Mass Spectrom. 2008 Sep;43(9):1215-23 [18324610.001]
  • [Cites] J Proteome Res. 2008 Sep;7(9):3776-88 [18642944.001]
  • [Cites] Mass Spectrom Rev. 1999 Nov-Dec;18(6):349-450 [10639030.001]
  • (PMID = 19113831.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R33 CA105295; United States / NCI NIH HHS / CA / R33 CA105295
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Lectins; 0 / Polysaccharides; 0 / fucose-binding lectin
  • [Other-IDs] NLM/ NIHMS496567; NLM/ PMC3739471
  •  go-up   go-down






Advertisement